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Abstract: An asymmetric total synthesis of the tris-oxazole marine 
macrolides, mycalolides A and B is described. This synthesis 
involves the convergent assembly of highly functionalized C1–C19 
tris-oxazole and C20–C35 side-chain segments through the use of 
olefin metathesis and esterification, as well as Julia–Kocienski 
olefination and enamide formation as key steps. 
Mycalolides are cytotoxic and antimycotic tris-oxazole 
macrolides, which was isolated from the marine sponge Mycale 
sp.[1] They inhibit actomyosin Mg2+–ATPase [2] and show potent 
actin-depolymerizing activity by forming a 1:1 complex with 
monomeric molecule.[3] Mycalolide B (1) contains a 2,3-O-
dimethyl-D-glyceryl ester moiety and 13 asymmetric centers as 
structural features, while a closely related mycalolide A (2) 
contains a ketone functionality at C30. Several tris-oxazole 
macrolides that are closely related to mycalolides have been 
isolated, such as ulapualides,[4] halichondramides,[5] 
jaspisamides,[6] and kabiramides;[7] all of these exhibit actin-
depolymerizing activity and potent cytotoxicity, and some induce 
apoptosis in tumor cells.[8] Thus, these agents may be useful for 
the design and development of novel pharmacological tools for 
analyzing actin-mediated cell functions, such as muscle 
contraction, cell motility, and cytokinesis, as well as those of 
therapeutic agents.[9] 
Mycalolides can be divided into two structurally 
characteristic parts: the C1–C24 tris-oxazole macrolactone and 
the C25–C35 side-chain functionalized by N-methyl enamide 
moiety. Studies on the structure–activity relationships [10] and 
photolabeling experiments [11] have established that the side-
chain part of mycalolides is important for its ability to bind to and 
depolymerize actin. In addition, X-ray analyses of the actin–
kabiramide C,[12] actin–jaspisamide A,[12] and actin–ulapualide A 
complexes [13] have revealed that their side-chain parts 
intercalate into the hydrophobic cleft between subdomains 1 and 
3 of actin. Meanwhile, we recently synthesized the 19E- and 
19Z-lactone analogs of mycalolides that lack the C25–C35 side-
chain; these analogs exhibited moderate cytotoxicity against 
tumor cells (ca. 1/100 of 1), but did not show actin-
depolymerizing properties or antimycotic activity against 
pathogenic fungi.[14] Thus, both the side-chain and macrolactone 
moieties were suggested to be essential for the potent biological 
activities of the parent molecules.  
 
Scheme 1.  Strategies for the synthesis of mycalolides A and B. 
 Due to their extraordinary structures and biological 
activities, mycalolides and their congeners have received 
considerable attention in the synthetic community, and several 
approaches to the construction of conformationally-restricted 
tris-oxazole macrolactone structures have been described.[15] To 
date, total syntheses of mycalolide A (2) [16] and ulapualide A [17] 
have been accomplished, in which Yamaguchi lactonization, 
cyclization of the central oxazole ring, or intramolecular Horner–
Wadsworth–Emmons olefination were used to construct 
macrocycles. However, no total synthesis of mycalolide B has 
been disclosed to date. We describe here the first total synthesis 
of (–)-mycalolide B (1) and the second synthesis of mycalolide A 
(2) through the use of olefin metathesis as a key step. 
Based on the finding that olefin metathesis is a useful 
method for connecting the C19–C20 double bonds in mycalolide 
analogs,[10c,18] we designed a plan for the synthesis of 1 
(Scheme 1). After disconnection of the C35 N-methyl enamide 
moiety and the C30 ester bond, the macrolactone structure of 1 
could be divided into a C1–C19 tris-oxazole segment 3 and a 
C20–C35 side-chain segment 4. We expected that the 
convergent assembly of 3 and 4 via esterification / ring-closing 
metathesis (RCM) would efficiently afford a key macrolactone. 
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Instead, cross metathesis of 3 and 4, in which the carboxyl or 
hydroxyl groups are protected, and subsequent 
macrolactonization could also provide the same intermediate. 
While the side-chain segment 4 was previously synthesized,[10,18] 
in this study we planned to modify the synthetic route, which 
includes the Julia–Kocienski olefination [19] between phenyl 
tetrazole (PT)-sulfone 5 and aldehyde 6. 
Our synthesis started with the preparation of 5 (Scheme 2). 
Methylation of the known syn-aldol 7 [10b] with methyl 
trifluoromethanesulfonate (MeOTf) and removal of the chiral 
auxiliary with LiBH4 yielded primary alcohol 8. Conversion of 8 
into the PT-sulfide with aryl disulfide/Bu3P and subsequent 
oxidation with m-CPBA yielded PT-sulfone 5.  
 
Scheme 2.  Synthesis of the C20–C35 segment 4. Reagents and conditions: 
a) MeOTf, 2,6-di-tert-butylpyridine, CH2Cl2; b) LiBH4, EtOH, Et2O–THF,  
–10 °C; c) 5,5'-dithiobis(1-phenyl-1H-tetrazole), tri-n-butylphosphine, THF; d) 
mCPBA, NaHCO3, CH2Cl2; e) H2, Pd(OH)2/C (20 mol%), NaHCO3, EtOH; f) 
3,4-dimethoxybenzyloxymethyl chloride, i-Pr2NEt, CH2Cl2; g) NH4F, MeOH, 
40 °C; h) Dess–Martin periodinane, pyridine, CH2Cl2; i) CH2=CHCH2MgBr, 
THF–Et2O; j) MeI, NaH, THF; k) nBu4NF, THF, rt to 40 °C. 
Next, Julia–Kocienski coupling was examined. Despite the 
sterically hindered, branched structures of both starting 
materials, treatment of 5 with LHMDS followed by the addition of 
aldehyde 6 [20] in THF at –78 °C afforded olefin 9 in 60% yield 
(condition A, E/Z = 1.2/1). After several attempts, the yield was 
improved to 92% (condition B, E/Z = 1/1.5) with the use of the 
same base in 1,2-dimethoxyethane (DME) at –55 °C to room 
temperature. While an excess amount of PT-sulfone 5 (2.5 eq.) 
was required to complete the reaction, this material was 
recovered quantitatively and reused.  
Catalytic hydrogenation of the C=C double bond and 
hydrogenolysis of the benzyl group from the E/Z-mixture of 9 
proceeded concurrently with palladium (II) hydroxide on carbon. 
Subsequent protection of the C30 hydroxy group as a 3,4-
dimethoxyphenylmethoxymethyl (DMPMOM) group afforded 
previously synthesized ether 10.[10b] Selective deprotection of the 
TBS group in 10 with NH4F and oxidation of the primary alcohol 
with Dess–Martin periodinane provided aldehyde 11. Grignard 
reaction of 11 with allylmagnesium bromide resulted in a mixture 
of S- and R-alcohol 12 (dr = 2.7/1), which were separated by 
column chromatography.[21] Finally, methylation of the secondary 
alcohol in 22S-12 and deprotection of the remaining TBS group 
with tetra-n-butylammonium fluoride (TBAF) gave the C20–C35 
segment 4.  
With the side-chain segment 4 in hand, we initially 
considered the RCM approach to reduce unnecessary protection 
/ deprotection steps (Scheme 3). Condensation of the C1–C19 
segment 3 [18] with 4 by the Shiina procedure using 2-methyl-6-
nitrobenzoic anhydride (MNBA) [22] afforded the RCM precursor 
13. We previously reported that treatment of 13 with 30 mol% of 
2nd-generation Grubbs catalyst (17a) [23] in degassed refluxing 
toluene led to the decomposition of the starting material (entry 
1).[18] However, in refluxing CH2Cl2, tris-oxazole lactone 15 was 
obtained as an E/Z mixture (40%, E/Z = 1.9:1, entry 2), while the 
reaction did not run to completion.  
 
Scheme 3.  Synthesis of macrolactones 15 and 16 via ring-closing metathesis.  
Due to the instability of catalyst 17a for the slow 
metathesis reaction of macrocycle precursors, we next 
examined 2nd-generation Hoveyda–Grubbs (HG-II) catalyst 
(17b).[24] We previously reported that treatment of 13 with 30 
mol% 17b in refluxing toluene afforded the RCM product 15 in 
higher yield but with undesired C19–C20 Z-isomer slightly 
preferred (76%, E/Z = 1/1.2, entry 3).[18] Meanwhile, in the model 
RCM reactions of C1–C24 macrolactone analogs, the solvent 
polarity was found to significantly affect the stereoselectivity; the 





Z-isomer was preferred in n-hexane and toluene (E/Z = 
1/1.9~2.5), while the E-isomer was preferred in CH2Cl2 (E/Z = 
1.8/1).[14] In fact, for the RCM reaction of 13 with 17b in refluxing 
CH2Cl2, the ratio was improved to 2.0:1, but the reaction did not 
run to completion, similar to the use of 17a (entry 4). These 
results suggested that the C25–C35 segment in 13 minimally 
affected the stereoselectivity, but decreased the reactivity for 
RCM reactions, probably due to the steric hindrance in forming 
the ruthenocyclobutane intermediate. Under refluxing conditions 
in 1,2-dichloroethane (DCE), the stereoselectivity decreased to 
1.0:1 (entry 5). To facilitate the initiation of the catalytic cycle at 
lower temperature, two highly reactive HG-II catalyst derivatives 
17c (Grela catalyst) [25] and 17d (Zhan catalyst 1B) [26] were 
examined, in which nitro or N,N-dimethylsulfonamide groups are 
substituted on the 2-isopropoxybenzylidene ligand. Notably, the 
use of both electron-deficient catalysts similarly increased the 
yield of 15 to 69–75%, while stereoselectivity was still low (E/Z = 
1.6–1.7/1, entries 6 and 7). We expected that such low 
stereoselectivity of RCM precursor 13 was due to the presence 
of structurally hindered C3 TBDPS group. For comparison, a C3 
hydroxy analog 14 was prepared from 13 by the treatment with 
TBAF along with acetic acid (AcOH). With the use of catalyst 
17c in refluxing CH2Cl2, the stereoselectivity of C3 hydroxy 
macrolactone 16 was improved to 2.7:1, but the yield was lower 
than that of 15 (entry 8).  
 
Scheme 4.  Synthesis of 15 via macrolactonization. Reagents and conditions: 
a) 2,2,2-trichloroethanol, EDCI·HCl, DMAP, CH2Cl2; b) TESCl, ImH, DMF, 
40 °C; c) 17b (20 mol%), CH2Cl2, reflux; d) AcOH–THF–H2O; e) Zn, 1 M 
NH4OAc aq., THF; f) 2,4,6-trichlorobenzoyl chloride, i-Pr2NEt, benzene, then 
dropwise addition into DMAP in benzene. 
A cross metathesis / macrolactonization approach was 
examined next (Scheme 4). Condensation of carboxylic acid 3 
with 2,2,2-trichloroethanol provided trichloroethyl (TCE) ester 18. 
Triethylsilyl (TES) protection of the secondary alcohol in 4 gave 
silyl ether 19. In contrast to the RCM reactions, treatment of 18 
and 19 (1.2 equiv.) with 20 mol% of HG-II catalyst (17b) in 
refluxing CH2Cl2 (13 mM for 18) preferentially yielded the 
coupling product 20 in an E-selective manner (E/Z = 5.0:1).[27] 
After the TES group in (E)-20 was removed under mild acidic 
conditions, the resultant alcohol was treated with activated zinc 
in acetate buffer to afford seco acid 21. Macrolactonization of 21 
by the Yamaguchi procedure [28] readily proceeded to give the 
lactone 15. Due to the higher stereoselectivity, the cross 
metathesis-macrolactonization approach was preferred to the 
RCM approach.  
The stage was then set for functionalization of the last 
side-chain part (Scheme 5). Acidic hydrolysis of the C35 methyl 
acetal in 15 afforded hemiacetal 22. Selective reductions of the 
five-membered hemiacetal in 22 using conventional hydride 
reagents were unsuccessful.[29] To our delight, however, Luche 
reduction of 22 at –20 °C exclusively led to 1,2-reduction of the 
C7 ketone followed by C35 hemiacetal reduction at 0 °C to 
afford triol 23 quantitatively (dr = 10:1 at C7). Next, trityl group 
protection of the primary alcohol, and chemoselective oxidation 
of the allylic alcohol with manganese dioxide gave ketone 24. 
Subsequent acetylation of the remaining C32 secondary alcohol, 
removal of the trityl group with formic acid in ether, and oxidation 
of the primary alcohol with Dess–Martin periodinane gave 
aldehyde 25. Dehydrating condensation with N-
methylformamide under acidic conditions,[30] and deprotection of 
the DMPMOM group with 2,3-dichloro-5,6-dicyano-p-
benzoquinone (DDQ) afforded secondary alcohol 26.  
 
Scheme 5.  Synthesis of mycalolides A and B. Reagents and conditions: a) 1 
M HCl aq., 1,2-dimethoxyethane; b) NaBH4, CeCl3·7H2O, MeOH, –20 to 0 °C; 
c) TrCl, pyridine; d) MnO2, CH2Cl2; e) Ac2O, DMAP, pyridine; f) HCOOH, Et2O; 
g) Dess–Martin periodinane, pyridine, CH2Cl2; h) MeNHCHO, PPTS, 
hydroquinone, MS3A, benzene, reflux; i) DDQ, CH2Cl2, tBuOH, 1 M phosphate 
buffer (pH 6.0); j) 2,3-di-O-methyl-D-glyceric acid, 2,4,6-trichlorobenzoyl 
chloride, Et3N, DMAP, benzene; k) nBu4NF, AcOH, THF.   
Finally, condensation of 26 with 2,3-di-O-methyl-D-glyceric 
acid using the Yamaguchi procedure and removal of the C3 
TBDPS group by TBAF along with AcOH furnished mycalolide B 
(1) in analytically pure form. The 1H and 13C NMR spectra of the 
synthetic mycalolide B are consistent with those of the natural 
product, along with its specific optical rotation {[α]D25 –55 (c 0.55, 





CHCl3) for synthetic 1; [α]D –53 (c 1.3, CHCl3) for natural 1 [1a]}. 
Synthetic 1 was also identical to an authentic sample on the 
basis of TLC and HPLC analysis. In addition, oxidation of the 
secondary alcohol in 26 with Dess–Martin periodinane gave 
authentic TBDPS-protected mycalolide A,[16] and removal of the 
TBDPS group afforded mycalolide A (2), whose 1H NMR data 
coincided with the reported one.[1a,16]  
In summary, we have developed a convergent approach 
for the synthesis of the tris-oxazole marine macrolides, and 
completed total synthesis of mycalolides A and B. The key 
elements in this synthesis include the use of RCM / cross 
metathesis and esterification as fragment coupling technology 
for complex building blocks that possess a variety of functional 
groups. Further studies on the synthesis and structure-activity 
relationships of mycalolides and related actin-targeting natural 
products, as well as on their mechanisms of action, are currently 
underway.  
Keywords: marine natural product • total synthesis • olefin 
metathesis • macrolactonization  
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